A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 65
Healthy Volunteers: f
View:
• Men or women between ≥19 and ≤65 years of age at the time of informed consent
• Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT \< 95% at Screening and Day 1/Baseline
• Current episode of hair loss for ≥6 months but \<8 years
• Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
• Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study
Locations
Other Locations
Republic of Korea
Kyung Hee University Hospital at Gangdong
RECRUITING
Seoul
Seoul National University Hospital.
RECRUITING
Seoul
Contact Information
Primary
Heesun Kim
flower@nextgenbio.co.kr
82-31-606-3220
Backup
YangHye Park
yhpark@nextgenbio.co.kr
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2027-01-31
Participants
Target number of participants: 73
Treatments
Experimental: NXC736
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: NEXTGEN Bioscience